Bar-Yehuda S - Search Results

1

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease.

Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R, Amital H, Reitblat T, Reitblat A, Ophir J, Konfino I, Chowers Y, Ben-Horin S, Fishman P. Ochaion A, et al. Cell Immunol. 2009;258(2):115-22. doi: 10.1016/j.cellimm.2009.03.020. Epub 2009 May 7. Cell Immunol. 2009. PMID: 19426966

2

The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.

Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P. Madi L, et al. Clin Cancer Res. 2004 Jul 1;10(13):4472-9. doi: 10.1158/1078-0432.CCR-03-0651. Clin Cancer Res. 2004. PMID: 15240539

3

Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.

Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman P. Ochaion A, et al. Arthritis Res Ther. 2006;8(6):R169. doi: 10.1186/ar2078. Arthritis Res Ther. 2006. PMID: 17101059 Free PMC article.

4

Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level.

Madi L, Cohen S, Ochayin A, Bar-Yehuda S, Barer F, Fishman P. Madi L, et al. J Rheumatol. 2007 Jan;34(1):20-6. J Rheumatol. 2007. PMID: 17216675

5

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.

Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. Bar-Yehuda S, et al. Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. doi: 10.1517/13543784.16.10.1601. Expert Opin Investig Drugs. 2007. PMID: 17922624 Review.

6

A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.

Cohen S, Barer F, Bar-Yehuda S, IJzerman AP, Jacobson KA, Fishman P. Cohen S, et al. Among authors: bar yehuda s. Mediators Inflamm. 2014;2014:708746. doi: 10.1155/2014/708746. Epub 2014 Oct 13. Mediators Inflamm. 2014. PMID: 25374446 Free PMC article.

7

The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. Ochaion A, et al. Biochem Pharmacol. 2008 Aug 15;76(4):482-94. doi: 10.1016/j.bcp.2008.05.032. Epub 2008 Jun 17. Biochem Pharmacol. 2008. PMID: 18602896 Free PMC article.

8

CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.

Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. Cohen S, et al. J Cell Physiol. 2011 Sep;226(9):2438-47. doi: 10.1002/jcp.22593. J Cell Physiol. 2011. PMID: 21660967 Free PMC article.

9

A3 adenosine receptor as a target for cancer therapy.

Fishman P, Bar-Yehuda S, Madi L, Cohn I. Fishman P, et al. Anticancer Drugs. 2002 Jun;13(5):437-43. doi: 10.1097/00001813-200206000-00001. Anticancer Drugs. 2002. PMID: 12045454 Review.

10

Pharmacology and therapeutic applications of A3 receptor subtype.

Fishman P, Bar-Yehuda S. Fishman P, et al. Curr Top Med Chem. 2003;3(4):463-9. doi: 10.2174/1568026033392147. Curr Top Med Chem. 2003. PMID: 12570762 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters